Subjects with low-density lipoprotein cholesterol < 130 mg/dL and heightened immune activation ( % CD8 ( + ) CD38 ( + ) HLA-DR ( + ) 19 % , or plasma high-sensitivity C-reactive protein 2 mg/L ) were randomized to receive rosuvastatin or placebo .